JG

Jeff Goater

Partner at The Column Group

Greater Boston

Overview 

Jeff Goater is a Partner at The Column Group with a strong background in corporate finance, mergers & acquisitions, and venture capital. He has served on the boards of multiple biotech companies and has made successful investments in companies like Kenai Therapeutics and Atavistik Bio. Highlights of Jeff's career include his role as a Partner at The Column Group, where he contributes expertise in corporate development and valuation, and his successful investments in early-stage companies like Kenai Therapeutics and Atavistik Bio.

Work Experience 

  • Board Member

    2024 - Current

  • Board Member

    2024

NILO Therapeutics is a biotechnology and therapeutics company.

Raised $9,600,002.00.

  • Board Member

    2024

Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders.

Raised $89,000,000.00 from The Column Group, Cure Ventures, Saisei Ventures, Euclidean Capital and Alaska Permanent Fund.

  • Partner

    2024

  • Venture Partner

    2021 - 2023

  • Board Member

    2023

Remix Therapeutics is a biotechnology company that is working on developing small molecule medicines.

Raised $211,000,000.00 from Surveyor Capital, The Column Group, Atlas Venture, Alexandria Venture Investments, Casdin Capital, ARCH Venture Partners, Foresite Capital, WTT Investment and Willett Advisors LLC.

  • Chair

    2023

  • Executive Chair

    2022

  • Board Member

    2022

Kallyope uses the science of gut-brain biology to create medicines that transform human health.

Raised $487,200,000.00 from Bill & Melinda Gates Foundation.

  • Board Member

    2021

  • Interim CEO

    2022 - 2023

Atavistik Bio is a biotechnology company that focuses on the discovery and development of novel therapies for metabolic diseases and cancer.

Raised $100,000,000.00 from Lux Capital, Nextech Invest and The Column Group.

  • Board Member

    2021 - 2024

Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.

Raised $259,000,001.00 from Pfizer Venture Investments.

Articles About Jeff

Relevant Websites